What is the management of Granulosa theca cell tumors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Granulosa Theca Cell Tumors

The management of granulosa theca cell tumors should prioritize fertility-sparing surgery for early-stage disease in young patients, with unilateral salpingo-oophorectomy being the standard surgical approach, while reserving adjuvant chemotherapy for advanced stages or high-risk features. 1

Diagnostic Workup

  • Initial evaluation should include pelvic ultrasound, abdomino-pelvic CT scan, chest X-ray, and in selected cases, PET scan 1
  • Laboratory tests should include tumor markers such as inhibin B, estradiol, LDH, and in young patients, complete blood count and liver and renal function tests 1
  • Histological confirmation by an expert pathologist is essential, with immunohistochemistry panel including inhibin alpha, calretinin, and FOXL2 in morphologically ambiguous cases 1

Surgical Management

Early-Stage Disease (Stage I)

  • For young patients desiring fertility preservation:

    • Unilateral salpingo-oophorectomy with preservation of the contralateral ovary and uterus is the standard surgical treatment 1
    • No systematic biopsy of the contralateral ovary is necessary when it appears macroscopically normal 1
    • Endometrial curettage must be performed to rule out concomitant uterine cancers 1
    • Retroperitoneal lymph node dissection is not mandatory due to the very low incidence of retroperitoneal metastases in early-stage disease 1
  • For postmenopausal women or those with completed childbearing:

    • Abdominal hysterectomy and bilateral salpingo-oophorectomy with careful surgical staging 1

Advanced-Stage Disease (Stage II-IV)

  • Debulking surgery remains the most effective treatment of advanced or recurrent granulosa cell tumors 1
  • Fertility-sparing surgery should be considered even in advanced disease due to the high chemosensitivity of these tumors 1
  • Nodal debulking surgery is only required in cases of residual disease after chemotherapy 1

Adjuvant Therapy

Early-Stage Disease (Stage I)

  • Stage IA adult granulosa cell tumor has excellent prognosis after surgery alone and does not require adjuvant therapy 1
  • Adjuvant therapy should be considered for:
    • Juvenile granulosa tumor stage IC patients 1, 2
    • Adult granulosa cell tumor stage IC2-IC3 patients 1
    • Patients with high mitotic index 1

Advanced-Stage Disease (Stage II-IV)

  • Platinum-based chemotherapy is the treatment of choice 1
  • BEP (bleomycin, etoposide, cisplatin) regimen is most commonly used:
    • Three cycles for completely resected disease 1
    • Four cycles for patients with macroscopic residual disease (bleomycin should be omitted after the third cycle to reduce lung toxicity) 1
  • Alternative chemotherapy options include:
    • Paclitaxel and carboplatin 1
    • Etoposide and cisplatin (EP) 1
    • Cyclophosphamide, doxorubicin, and cisplatin (CAP) 1

Recurrent Disease Management

  • Debulking surgery is the most effective treatment when feasible 1
  • For platinum-sensitive relapse (progression >4-6 weeks after completion of chemotherapy), platinum-based combinations should be considered 1
  • For platinum-resistant disease, options include:
    • VAC (vincristine, actinomycin D, cyclophosphamide) 1
    • Paclitaxel/gemcitabine 1
    • Gemcitabine/oxaliplatin 1
  • Hormonal therapies including GnRH agonists, tamoxifen, progestins, and aromatase inhibitors have shown responses in adult granulosa cell tumors 1

Follow-up

  • Follow-up visits should include history, physical examination with pelvic examination, and tumor markers every 3 months for the first 2 years, then every 6 months during years 3-5 1
  • Long-term follow-up is essential as recurrences can occur up to 20 years after primary diagnosis 1
  • Pelvic ultrasound and CT scan of abdomen, pelvis, and chest (if lung metastases are suspected) are the most common imaging techniques for surveillance 1
  • Serum tumor markers including inhibin B, estradiol, and AMH (anti-Müllerian hormone) can be useful for monitoring 1

Special Considerations and Pitfalls

  • Tumor rupture during surgery should be avoided as it may upstage the disease and require adjuvant chemotherapy 3, 4
  • Fertility outcomes are generally favorable after fertility-sparing surgery, with multiple reports of successful pregnancies 5, 4, 6
  • After completion of family planning, completion surgery with hysterectomy and removal of remaining adnexa should be considered due to the risk of late recurrence 6
  • The indolent nature of these tumors requires long-term surveillance, as recurrences can occur decades after initial diagnosis 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Juvenile Granulosa Cell Tumor of the Ovary: A Clinicopathologic Study.

Journal of pediatric and adolescent gynecology, 2017

Research

Stage I juvenile granulosa cell tumors of the ovary: A multicentre analysis from the MITO-9 study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021

Research

Juvenile granulosa cell ovarian tumor: clinicopathological evaluation of ten patients.

Journal of the Turkish German Gynecological Association, 2015

Research

Fertility sparing management and pregnancy in patients with granulosa cell tumour of the ovaries.

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.